---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-23-000140"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:20:03.190818+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q2 revenue $90.3M (+24% YoY); GM Urological Cancers Tina Nova resigns

## Summary
- Total revenue $90.3M (+24% YoY); testing revenue $81.7M (+37%); test volume 31,809 (+28%).
- Net loss $8.4M (-$0.12 EPS), improved 12% YoY; cash from ops $17M in Q2; cash $191M.
- Biopharma revenue $4.6M (-55% YoY); product revenue $4.0M (+29%).
- Tina Nova resigns as GM Urological Cancers (eff. Sept 3); advisor role $10k/month for 12 months.

## SEC filing metadata
- accession: 0001384101-23-000140
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/0001384101-23-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/vcyt-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-23-000140
- JSON: https://secwatch.observer/filing/0001384101-23-000140.json
- Plain text: https://secwatch.observer/filing/0001384101-23-000140.txt

## Key facts
- Earnings Releases
  VERACYTE, INC. reported the second quarter ended June 30, 2023 results: revenue $90.3 million, net income Net loss for the second quarter of 2023 was $8.4 million, EPS Basic and diluted net loss per common share was $0.12.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $90.3 million
  - Net income: Net loss for the second quarter of 2023 was $8.4 million
  - EPS: Basic and diluted net loss per common share was $0.12
  - Result: reported results
  source text: Second Quarter 2023 Financial Results Total revenue for the second quarter of 2023 was $90.3 million, an increase of 24% compared to $72.9 million reported in the second quarter of 2022. Testing revenue was $81.7 million, an increase of 37% compared to $59.7 million in the second quarter of 2022 driven primarily by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $4.0 million, an increase of 29% compared to $3.1 million in the second quarter of 2022. Biopharmaceutical and other revenue was $4.6 million, a decrease of 55% compared to $10.0 million in the second quarter of 2022. Total gross margin for the second quarter of 2023, including the amortization of acquired intangible assets, was 62%, compared to 59% in the second quarter of 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 67%, compared to 66% in the second quarter of 2022. Operating expenses, excluding cost of r
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/0001384101-23-000140-index.htm
- Executive change
  Tina S. Nova departed as General Manager, Urological Cancers at VERACYTE, INC..
  - Action: resign
  - Role: General Manager, Urological Cancers
  source text: On August 4, 2023, the Company and Tina S. Nova, Ph.D. agreed that Dr. Nova will resign from her position as General Manager, Urological Cancers of the Company effective as of September 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/0001384101-23-000140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.